Thursday, December 06, 2018
Icagen announced today that they have entered into a license and collaboration agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of neurological disorders. The program incorporates Icagen's platform for ion channels and is directed at a specific novel ion channel target expressed in neurons.
"We are excited about partnering with Roche to develop treatments for difficult to treat neurological diseases and look forward to collaborating with them to help bring medicines to patients," said Icagen CEO Richie Cunningham. "Roche has a great track record of partnering with biotech firms in addition to unique development expertise and a strong global commercial presence. This collaboration is a great example of combining Icagen's depth and expertise in ion channel drug discovery with the therapeutic area and developmental expertise of a company like Roche to enhance the likelihood of identifying meaningful new therapies."